The behavioural companion for GLP-1 treatment
GLP-1 receptor agonists are transforming obesity treatment — but medication alone isn't enough. Lasting results need behavioural change alongside pharmacotherapy. Evira provides the monitoring, communication and lifestyle support that make GLP-1 treatment more effective.
Why Evira alongside GLP-1 medication
Around 10% of children in UK CEW services using Evira are now also receiving GLP-1 medication. Some services make Evira mandatory before starting GLP-1s — to demonstrate commitment and establish behavioural foundations first.
Prove commitment before prescribing
Some clinicians require patients to demonstrate engagement with Evira before starting GLP-1 treatment. Daily measurements provide objective evidence of commitment.
Dosing communication
Dedicated messaging for GLP-1 dosing — titration schedules, side-effect reporting and adjustment discussions. All in-app, all documented, all in one place.
Separate medication from behaviour
Continuous data alongside medication start dates lets you distinguish the medication effect from behavioural change — informing decisions about continuation or stepping down.
Objective monitoring during medication
Daily measurements give continuous, objective data on weight response — no reliance on clinic weigh-ins months apart.
Behavioural foundation — no weight regain
GLP-1s reduce appetite, but weight regain after discontinuation is well documented. Evira three-year data shows no weight regain — the lifestyle habits sustain the result.
Side-effect monitoring
Patients and families report GLP-1 side effects via messaging. Rapid weight changes trigger alerts — intervene early if response is too aggressive or insufficient.
How it works in practice
Whether GLP-1 medication comes before, during or after starting Evira — the platform adapts to your clinical pathway.
- 1
Establish baseline
Patient starts Evira. Daily measurements establish a behavioural baseline.
- 2
GLP-1 decision
Clinician reviews Evira data alongside their clinical assessment.
- 3
Start medication
GLP-1 titration begins. Daily data shows response in real time.
- 4
Dose communication
In-app messaging for dosing queries, side effects, titration.
- 5
Monitor response
Dashboard shows the weight trend overlaid with the medication timeline.
- 6
Sustain long-term
Behavioural change continues alongside or after medication.
GLP-1s in paediatric obesity
GLP-1 receptor agonists are increasingly used in paediatric and adult weight management. In UK CEW services using Evira, around 10% of children are now on concurrent GLP-1 treatment. As prescribing grows, structured behavioural monitoring alongside medication becomes critical.
Evira is not a substitute for pharmacotherapy — it is the behavioural infrastructure that makes medication more effective and supports sustained outcomes. Three-year data shows no weight regain in the Evira group, in contrast to known rebound effects after medication is discontinued.
A randomised controlled trial testing Evira for adolescents on GLP-1 medication is underway at five university clinics in Sweden (initiated 2025).
Discuss GLP-1 support for your service
We'll show you how Evira integrates with your prescribing pathway — paediatric or adult.